Sichuan Hebang Biotechnology Co (SHSE:603077) Cyclically Adjusted Revenue per Share: ¥0.89 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603077 Sichuan Hebang Biotechnology Co Ltd SHSE:603077
53 GF Score
Price ¥2.35
GF Value ¥1.27
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Sichuan Hebang Biotechnology Co Cyclically Adjusted Revenue per Share?

Sichuan Hebang Biotechnology Co SHSE:603077 -0.84% 53 Cyclically Adjusted Revenue per Share is ¥0.89 as of Jun. 2026. GuruFocus rates SHSE:603077 with a GF Score™ of 53/100 and a GF Value™ of ¥1.27 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sichuan Hebang Biotechnology Co's adjusted revenue per share for the three months ended in Jun. 2026 was ¥0.144. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥0.89 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Sichuan Hebang Biotechnology Co's average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sichuan Hebang Biotechnology Co was 14.20% per year. The lowest was 6.90% per year. And the median was 11.70% per year.

As of today (2026-08-23), Sichuan Hebang Biotechnology Co's current stock price is ¥2.35. Sichuan Hebang Biotechnology Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ¥0.89. Sichuan Hebang Biotechnology Co's Cyclically Adjusted PS Ratio of today is 2.64.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sichuan Hebang Biotechnology Co was 8.31. The lowest was 1.97. And the median was 3.04.


Sichuan Hebang Biotechnology Co  (SHSE:603077) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sichuan Hebang Biotechnology Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.35/0.89
=2.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sichuan Hebang Biotechnology Co was 8.31. The lowest was 1.97. And the median was 3.04.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sichuan Hebang Biotechnology Co Cyclically Adjusted Revenue per Share Related Terms


Sichuan Hebang Biotechnology Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Sichuan Hebang Biotechnology Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sichuan Hebang Biotechnology Co Cyclically Adjusted Revenue per Share Chart

Sichuan Hebang Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.72 0.79 0.85 0.88

Sichuan Hebang Biotechnology Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 0.88 0.88 0.89 0.89

SHSE:603077 vs DOW: Cyclically Adjusted Revenue per Share Comparison

For the Chemicals subindustry, Sichuan Hebang Biotechnology Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Hebang Biotechnology Co Cyclically Adjusted PS Ratio vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Sichuan Hebang Biotechnology Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sichuan Hebang Biotechnology Co's Cyclically Adjusted PS Ratio falls into.


SHSE:603077
53GF Score
Sichuan Hebang Biotechnology Co Ltd SHSE:603077
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sichuan Hebang Biotechnology Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sichuan Hebang Biotechnology Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.144/116.0564*116.0564
=0.144

Current CPI (Jun. 2026) = 116.0564.

Sichuan Hebang Biotechnology Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.147 102.400 0.167
201612 0.138 102.600 0.156
201703 0.108 103.200 0.121
201706 0.130 103.100 0.146
201709 0.145 104.100 0.162
201712 0.165 104.500 0.183
201803 0.231 105.300 0.255
201806 0.133 104.900 0.147
201809 0.188 106.600 0.205
201812 0.154 106.500 0.168
201903 0.126 107.700 0.136
201906 0.191 107.700 0.206
201909 0.202 109.800 0.214
201912 0.181 111.200 0.189
202003 0.131 112.300 0.135
202006 0.150 110.400 0.158
202009 0.179 111.700 0.186
202012 0.163 111.500 0.170
202103 0.203 112.662 0.209
202106 0.263 111.769 0.273
202109 0.376 112.215 0.389
202112 0.340 113.108 0.349
202203 0.355 114.335 0.360
202206 0.502 114.558 0.509
202209 0.350 115.339 0.352
202212 0.292 115.116 0.294
202303 0.275 115.116 0.277
202306 0.194 114.558 0.197
202309 0.268 115.339 0.270
202312 0.276 114.781 0.279
202403 0.242 115.227 0.244
202406 0.340 114.781 0.344
202409 0.242 115.785 0.243
202412 0.188 114.893 0.190
202503 0.165 115.116 0.166
202506 0.214 114.907 0.216
202509 0.201 115.471 0.202
202512 0.121 115.832 0.121
202603 0.135 116.303 0.135
202606 0.144 116.056 0.144

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥0.89 mean?
Sichuan Hebang Biotechnology Co (SHSE:603077) has a Cyclically Adjusted Revenue per Share of ¥0.89 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sichuan Hebang Biotechnology Co and its competitors.
Is Sichuan Hebang Biotechnology Co's Cyclically Adjusted Revenue per Share too high?
Sichuan Hebang Biotechnology Co's current Cyclically Adjusted Revenue per Share is ¥0.89. Overall, Sichuan Hebang Biotechnology Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Hebang Biotechnology Co's Cyclically Adjusted Revenue per Share compare to DOW?
Sichuan Hebang Biotechnology Co's Cyclically Adjusted Revenue per Share of ¥0.89 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Chemicals company?
A good Cyclically Adjusted Revenue per Share depends on the Chemicals industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sichuan Hebang Biotechnology Co and its competitors. Sichuan Hebang Biotechnology Co's current Cyclically Adjusted Revenue per Share is ¥0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Hebang Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Hebang Biotechnology Co (SHSE:603077) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥1.27, compared to a current price of ¥2.35 — trading 85% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥0.89. Sichuan Hebang Biotechnology Co's overall GF Score™ is 53/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Sichuan Hebang Biotechnology Co (SHSE:603077), the current Cyclically Adjusted Revenue per Share is ¥0.89 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sichuan Hebang Biotechnology Co (SHSE:603077) Overvalued in 2026?

Based on GuruFocus' analysis, Sichuan Hebang Biotechnology Co stock appears to be overvalued. The current stock price of ¥2.35 is trading 85% above its estimated GF Value™ of ¥1.27. GuruFocus considers Sichuan Hebang Biotechnology Co to be Significantly Overvalued.

Key valuation signals for SHSE:603077:

  • Cyclically Adjusted Revenue per Share: ¥0.89
  • GF Value™: ¥1.27 vs. price of ¥2.35 (85% above fair value)
  • GF Score™: 53/100 with 8 warning signs

No single metric tells the full story. See the SHSE:603077 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sichuan Hebang Biotechnology Co Business Description

Address Mianba Village, Niuhua Town, Wutongqiao District, Sichuan, Leshan, CHN, 614801
Sichuan Hebang Biotechnology Co Ltd is engaged in Chemical manufacturing and development of salt mines and phosphate mines.
53GF Score

Get the complete analysis for SHSE:603077

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥2.35
Price
¥1.27
GF Value